High-dose chemotherapy and peripheral blood stem cell infusion in patients with non-Hodgkin's lymphoma: Results of outpatient treatment in community cancer centers

Bone Marrow Transplantation

Volumn 20, Issue 9, 1997, Pages 753-760

  Weaver, C H ^a   Schwartzberg, L ^a   Zhen, B ^a   Mangum, M ^a   Leff, R ^a   Tauer, K ^a   Rosenberg, A ^a   Pendergrass, K ^a   Kaywin, P ^a   Hainsworth, J ^a   Greco, F A ^a   West, W H ^a   Buckner, C D ^a,b  

^a Response Oncology Inc   (United States)

^b Response Oncology Inc   (United States)

Author keywords

Autologous stem cells; High dose chemotherapy; Non Hodgkin's lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GROWTH FACTOR;

ARTICLE; CANCER CENTER; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG MEGADOSE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; OUTPATIENT CARE; PERIPHERAL BLOOD STEM CELL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; UNITED STATES;

EID: 0030669937     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700975     Document Type: Article

References (48)

1. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New Engl J Med 1995; 333: 1540-1545.
2. Armitage JO, Gingrich RD, Klassen LW et al. Trial of high-dose cytarabine, cyclophosphamide, total-body irradiation and autologous marrow transplantation for refractory lymphoma. Cancer Treat Rep 1986; 70: 871-875.
3. Appelbaum FR, Sullivan KM, Buckner CD et al. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. J Clin Oncol 1987; 5: 1340-1347.
4. Phillip T, Armitage JO, Spitzer G. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. New Engl J Med 1987; 316: 1493-1498.
5. Goldstone AH, Singer CRJ, Gribben JG, Jarrett M, Group FtEBMT. Fifth report of EBMTG experience of ABMT in malignant lymphoma. Bone Marrow Transplant 1988; 3: 33-36.
6. Brunvand MW, Appelbaum FR, Soll E et al. High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous marrow and peripheral blood stem cells. Bone Marrow Transplant 1996; 18: 131-141.
7. Gribben JG, Linch DC, Singer CRJ. Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 1989; 73: 340-344.
8. Gulati SC, Shank B, Black P et al. Autologous bone marrow transplantation for patients with poor-prognosis lymphoma. J Clin Oncol 1988; 6: 1303-1313.
9. Kessinger A, Armitage JO, Smith DM el al. High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood 1989; 74: 1260-1265.
10. Freedman AS, Takvorian T, Neuberg D et al. Autologous bone marrow transplantation in poor-prognosis intermediategrade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study. J Clin Oncol 1993; 11: 931-936.
11. Colombat P, Gorin NC, Lemonnier MP et al. The role of autologous bone marrow transplantation in 46 adult patients with non-Hodgkin's lymphomas. J Clin Oncol 1990; 8: 630-637.
12. Gulati S, Yahalom J, Acaba L et al. Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation. J Clin Oncol 1992; 10: 936-941.
13. Lazarus HM, Crilley P, Ciobanu N et al. High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma. J Clin Oncol 1992; 10: 1682-1689.
14. Wheeler C, Strawderman M, Ayash L et al. Prognostic factors for treatment outcome in autotransplantation of intermediategrade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. J Clin Oncol 1993; 11: 1085-1091.
15. Chopra R, McMillan AK, Linch DC et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 1993; 81: 1137-1145.
16. Vose JM, Anderson JR, Kessinger A et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1846-1851.
17. Petersen FB, Appelbaum FR, Hill R. Autologous marrow transplantation for malignant lymphoma. A report of 101 cases from Seattle. J Clin Oncol 1990; 8: 638-647.
18. Weaver CH, Petersen FB, Appelbaum FR et al. High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma. J Clin Oncol 1994; 12: 2559-2566.
19. Horning SJ, Negrin RS, Chao NJ et al. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 2552-2558.
20. Meehan KR, Pritchard RS, Leichter JW et al. Autologous bone marrow transplantation versus chemotherapy in relapsed/refractory non-Hodgkin's lymphoma: estimates of long-term survival from the recent literature (review). Am J Hematol 1995; 50: 116-123.
21. Rapoport AP, Rowe JM, Kouides PA et al. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome. J Clin Oncol 1993; 11: 2351-2361.
22. Mills W, Chopra R, McMillan A et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 588-595.
23. Shpall EJ, Jones RB. Dissemination and commercialization of hematopoietic progenitor cell transplantation (letter to Editor). J Hematother 1994; 3: 93-94.
24. Buckner CD. Reply to Editorial 'Dissemination and commercialization of hematopoietic progenitor cell transplantation'. J Hematother 1994; 3: 249-250.
25. Schwartzberg L, Birch R, Blanco R et al. Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy. Bone Marrow Transplant 1993; 11: 369-374.
26. Schiffman KS, Bensinger WI, Appelbaum FR et al. Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease. Bone Marrow Transplant 1996; 17: 943-940.
27. Weaver CH, Schwartzberg LS, Li W et al. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease. Bone Marrow Transplant 1996; 17: 715-721.
28. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
29. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112-2135.
30. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New Engl J Med 1993; 328: 1002-1006.
31. The American Society of Clinical Oncology and American Society of Hematology. Recommended criteria for the performance of bone marrow transplantation. J Clin Oncol 1990; 8: 563-564.
32. Schwartzberg L, Birch R, Hazelton B et al. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. J Hematother 1992; 1: 317-327.
33. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992; 10: 239-253.
34. Crawford SW. Critical care and respiratory failure. In: Thomas ED, Forman SJ, Blume K (eds). Bone Marrow Transplantation. Blackwell Scientific: Boston, 1994, pp 513-526.
35. Shuhart MC, McDonald GB. Gastrointestinal and hepatic complications. In: Forman SJ, Blume KG, Thomas ED (eds). Bone Marrow Transplant. Blackwell Scientific: Boston, 1994, pp 454-481.
36. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
37. Bast RC Jr, DeFabritiis P, Lipton J et al. Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Res 1985; 45: 499-503.
38. De Fabritiis P, Bregni M, Lipton J et al. Elimination of clonogenic Burkitt's lymphoma cells from human bone marrow using 4-hydroperoxycyclophosphamide in combination with monoclonal antibodies and complement. Blood 1985; 65: 1064-1070.
39. Kvalheim G, Sorensen O, Fodstad O et al. Immunomagnetic removal of B-lymphoma cells from human bone marrow: a procedure for clinical use. Bone Marrow Transplant 1988; 3: 31-11.
40. Weisdorf DJ, Haake R, Miller WJ et al. Autologous bone marrow transplantation for progressive non-Hodgkin's lymphoma: clinical impact of immunophenotype and in vitro purging. Bone Marrow Transplant 1991; 8: 135-142.
41. Gribben JG, Freedman AS, Woo SD et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplitiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 1991; 78: 3275-3280.
42. Hurd DD, LeBien TW, Lasky LC et al. Autologous bone marrow transplantation in non-Hodgkin's lymphoma: monoclonal antibodies plus complement for ex vivo marrow treatment. Am J Med 1988; 85: 829-834.
43. Preijers FWMB, De Witte T, Wessels JMC et al. Autologous transplantation of bone marrow purged in vitro with anti-CD7-(WT1-) ricin A immunotoxin in T-cell lymphoblastic leukemia and lymphoma. Blood 1989; 74: 1152-1158.
44. Williams CD, Goldstone AH, Pearce RM et al. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin Oncol 1996; 14: 2454-2464.
45. Negrin RS, Kusnierz-Glaz CR, Still BJ et al. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. Blood 1995; 85: 3334-3341.
46. Schiller G, Vescio R, Freytes C et al. Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 1995; 86: 390-397.
47. Pecego R, Hill R, Appelbaum FR et al. Interstitial pneumonitis following autologous bone marrow transplantation. Transplantation 1986; 42: 515-517.
48. Weaver CH, Appelbaum FR, Petersen FB et al. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy. J Clin Oncol 1993; 11: 1329-1335.